Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.

Saved in:
Bibliographic Details
Title: Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.
Authors: Maura F; Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA., Freeman CL; Moffitt Cancer Center, Tampa, FL, USA., Maclachlan KH; Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ilundain ML; Department of Hematology, Center for Applied Medical Research, Cancer Center Clinica Universidad de Navarra, IDISNA, CIBERONC, University of Navarra, Pamplona, Spain., Ziccheddu B; Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Meermeier EW; Mayo Clinic, Scottsdale, AZ, USA., Garces JJ; Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Durante M; Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA., Lee H; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada., Firestone R; Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Menges M; Moffitt Cancer Center, Tampa, FL, USA., Reid K; Moffitt Cancer Center, Tampa, FL, USA., Diamond B; Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA., Papadimitriou M; Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA., Silva AS; Moffitt Cancer Center, Tampa, FL, USA., Sudalagunta PR; Moffitt Cancer Center, Tampa, FL, USA., Leblay N; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada., Ahn S; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada., Fuller E; Dana Farber Cancer Institute, Boston, USA., Briercheck E; Dana Farber Cancer Institute, Boston, USA., Sharik ME; Mayo Clinic, Scottsdale, AZ, USA., Du MT; Mayo Clinic, Scottsdale, AZ, USA., Agius P; Moffitt Cancer Center, Tampa, FL, USA., Hansen DK; Moffitt Cancer Center, Tampa, FL, USA., Song X; Moffitt Cancer Center, Tampa, FL, USA., Zhao X; Moffitt Cancer Center, Tampa, FL, USA., Meads MB; Moffitt Cancer Center, Tampa, FL, USA., Teer J; Moffitt Cancer Center, Tampa, FL, USA., Jelinek T; Department of Haemato-oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Hagner P; Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.; Moffitt Cancer Center, Tampa, FL, USA.; Department of Hematology, Center for Applied Medical Research, Cancer Center Clinica Universidad de Navarra, IDISNA, CIBERONC, University of Navarra, Pamplona, Spain.; Mayo Clinic, Scottsdale, AZ, USA.; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada.; Dana Farber Cancer Institute, Boston, USA.; Department of Haemato-oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.; Executive Director, Translational Development, Bristol-Myers Squibb, Summit, NJ 07901., Baz R; Executive Director, Translational Development, Bristol-Myers Squibb, Summit, NJ 07901.; Moffitt Cancer Center, Tampa, FL, USA., Alsina M; Moffitt Cancer Center, Tampa, FL, USA., Ramasubramanian AM; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada., Smith E; Dana Farber Cancer Institute, Boston, USA., Giralt SA; Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Mailankody S; Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Bergsagel LP; Mayo Clinic, Scottsdale, AZ, USA., Neri P; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada., Chesi M; Mayo Clinic, Scottsdale, AZ, USA., Martinez-Climent JA; Department of Hematology, Center for Applied Medical Research, Cancer Center Clinica Universidad de Navarra, IDISNA, CIBERONC, University of Navarra, Pamplona, Spain., Locke FL; Moffitt Cancer Center, Tampa, FL, USA., Bahlis NJ; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada., Landgren O; Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA., Hamadeh I; Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Usmani SZ; Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Shain KH; Moffitt Cancer Center, Tampa, FL, USA.
Source: BioRxiv : the preprint server for biology [bioRxiv] 2025 Dec 11. Date of Electronic Publication: 2025 Dec 11.
Publication Type: Journal Article; Preprint
Journal Info: Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet ISSN: 2692-8205 (Electronic) Linking ISSN: 26928205 NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2692-8205
DOI:10.64898/2025.12.08.692978